A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 191 participants.

Also called NCT06616974

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 191 participants (planned count) (from the registry)
Sponsor
Tectonic Therapeutic (from the registry)
Registry
  • NCT NCT06616974
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States, Armenia, Australia, Austria, Belgium, Bulgaria, Georgia, Germany, Latvia, Moldova, New Zealand, Poland, Portugal, Romania, Serbia, Spain, Ukraine (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06616974. Randomized; double masking; primary purpose treatment. Start 2024-09-04 (actual); primary completion 2026-11-24 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
Intervention (Drug)
TX000045- Dose A
Intervention (Drug)
TX000045- Dose B
Intervention (Drug)
Placebo
Lead sponsor
Tectonic Therapeutic (class: industry)

Record details

Record id
cardio:ct-nct06616974
Content hash
4d4951a251c8ff5bbf0e980be9b00c4d7d42676d9087f73fbc11ffaec70c17e3